Compare WAFD & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | PHVS |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 1996 | 2020 |
| Metric | WAFD | PHVS |
|---|---|---|
| Price | $30.85 | $31.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $35.00 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 04-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 5.20 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $29,650,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | $12.79 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $26.31 | $20.65 |
| 52 Week High | $39.49 | $43.25 |
| Indicator | WAFD | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 23.21 | 33.82 |
| Support Level | $29.68 | $25.17 |
| Resistance Level | $33.78 | $33.33 |
| Average True Range (ATR) | 0.71 | 1.90 |
| MACD | -0.18 | -0.70 |
| Stochastic Oscillator | 11.51 | 8.90 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.